Pacritinib
Vonjo · JAK2/ACVR1 inhibitor
JAK2/ACVR1 inhibitor; diarrhea-driven prerenal AKI and electrolyte loss.
Piqray · ALP
PI3Kα inhibitor · approved 2019 · 7 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
PI3K-alpha inhibitor whose on-target hyperglycemia can drive osmotic diuresis and prerenal AKI — a metabolic, not structural, kidney threat.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Hyperglycemia is essentially on-target and very common: any-grade hyperglycemia ~64% and grade 3/4 hyperglycemia ~36.6% in SOLAR-1, with diabetic ketoacidosis reported rarely in pharmacovigilance. The renal injury is secondary (osmotic diuresis/volume depletion or DKA) rather than a direct lesion; a discrete AKI incidence is not well quantified.Source: Andre et al., N Engl J Med 2019 (SOLAR-1; 36.6% grade 3/4 hyperglycemia — a metabolic, not renal-injury, rate); Rugo et al., Ann Oncol 2020
Hyperglycemia typically within the first 1–2 weeks; prerenal AKI follows volume depletion or a hyperglycemic crisis.
Distilled from: “Hyperglycemia typically within the first 1-2 weeks; prerenal AKI follows volume depletion or a hyperglycemic crisis.”
Distilled from the agent's cited literature — educational, not a substitute for the primary sources.
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).
Direct death of tubular epithelial cells — the dose-limiting lesion of the platinums and zoledronate.
Tap a signature to trace where it strikes the nephron.
Functional / pre-renal — reduced perfusion upstream of the nephron; no single structural segment is injured.
Prerenal / Hemodynamic AKI: functional / pre-renal, no single structural segment injured.
Prerenal / Hemodynamic AKI
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Selective oral inhibitor of the p110-alpha catalytic isoform of class I PI3K (PIK3CA). In PIK3CA-mutated hormone-receptor-positive, HER2-negative breast cancer it blocks PI3K/AKT/mTOR signaling downstream of the activated receptor, restoring sensitivity to endocrine therapy (fulvestrant).
6 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.
Quoted verbatim from this agent's current FDA label (Oct 2026) — not paraphrased or interpreted. Full label on DailyMed .
Renal impairment — from the label
The effect of severe renal impairment (CLcr < 30 mL/min) on alpelisib pharmacokinetics is unknown [see Clinical Pharmacology (12.3)] . No dose adjustment is recommended for patients with mild to moderate renal impairment (CLcr 30 to < 90 mL/min).
Kidney rows of the label's dosage tables
From the PIQRAY label (Oct 2026) · DailyMed
No row of this label's 5 dosage tables names a kidney term together with a withhold, reduce, resume or discontinue instruction. That covers those four instructions in the tables only: a table can still set a starting dose by creatinine clearance, and the prose can give other kidney instructions. The full label on DailyMed has both.
Everything below is FAERS — adverse events someone chose to report, about 9,106 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Reported with a death outcome
1,331 of 9,106 reports
Reported with hospitalization
1,835 of 9,106 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial · 5 of the 9,106 reports predate 2015 and are not drawn.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Alpelisib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Vonjo · JAK2/ACVR1 inhibitor
JAK2/ACVR1 inhibitor; diarrhea-driven prerenal AKI and electrolyte loss.
Revtorpyk · Pan-PI3K inhibitor
2026 IV pan-PI3K + mTORC1/2 (breast); on-target hyperglycemia and low-grade Na/K/Mg drift — creatinine up 14% vs 8% control, grade 3-4 rare.
Amtagvi · Tumor-infiltrating lymphocyte (TIL) therapy
2024 cellular therapy; high-dose IL-2 conditioning → capillary leak AKI.
Avmapki (co-packaged with defactinib as Avmapki Fakzynja) · RAF/MEK inhibitor
RAF/MEK clamp; CK elevation/rhabdomyolysis and tubular electrolyte wasting.
Nerlynx · HER2 / pan-EGFR TKI
Severe diarrhea → prerenal AKI; loperamide prophylaxis.
Truqap · AKT inhibitor
2023 breast-cancer AKT inhibitor; AKI with diarrhea/hyperglycemia.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.
The leading contributors to Alpelisib’s clinical kidney literature on PubMed, ranked by a blend of publication volume and citation impact — filtered toward clinical work via the PubMed Humans heading and clinical publication types (trials, cohorts, case reports, guidelines, reviews). Names link to that author’s work on Alpelisib; the PMIDs beside each name are up to three of their most recent papers on it, not the full count.
Ranked by a 50/50 blend of publication volume and a position-weighted, capped Relative Citation Ratio (NIH iCite) on this agent’s renal literature; the citation count shown is the raw total, not the ranking score — counted over the 5 clinical records among all 6 PubMed matches, so counts are within-sample — bibliometric context, not an endorsement or a measure of clinical authority.